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Ashley Casimir Vasnaik, SRNA, BSN, RN, CCRN
Otterbein University, Westerville, Ohio
Introduction

The topic of Malignant hyperthermia
(MH) will be presented in this poster.
MH was chosen as the poster topic as
this is an anesthetic crisis that can occur
following the administration of
triggering agents. It is of the upmost
importance for the anesthesia providers,
as well as support staff, to be able to
recognize and respond to an MH crisis to
optimize the patient’s outcome.
Banek et al., (2013) stated that MH is a
rare but potentially lethal genetic
disease process that presents as muscle
hypermetabolism upon exposure to
certain anesthetic agents.
Butterworth et al., (2013) stated that
MH impacts:
1:3000 - 1:15,000 pediatric patients
1:40,000 adult patients
The higher incidence in the pediatric
population was seen in cases where both
a volatile agent and succinylcholine
were used.
Inhaled general/Volatile anesthetics/
Depolarizing muscle relaxants known to
trigger MH:
Desflurane
Sevoflurane
Isoflurane
Halothane
Enflurane
Ether
Methoxyflurane Succinylcholine
(Long & Ross, 2017).
Most reported cases have been in
young males, very few have been
reported in the geriatric population, and
none have been reported in infants, but
both sexes and all ages may be affected
(Butterworth et al., 2013).
MH incidences greatly differ from
country to country and even vary by
geographical location within the same
country. This illustrates that different
gene pools can be impacted by this
disease process. In the United States, the
upper Midwest appears to have the
greatest population of individuals that
are susceptible to MH (Butterworth et
al., 2013).
Inheritance patterns include:
Autosomal dominant
(Hines & Marschall, 2012).
Rosenberg et al., (2015) stated that
specific point mutations have been
found in the ryanodine receptor gene
(RYR1) which is located on chromosome
19. Abnormalities have also been found
on the dihydropyridine receptor.

Pathophysiological Process
Normal Physiology
Signs and Symptoms
To understand the pathophysiology of
MH, one must first understand the
normal physiology of muscle contraction.
In normal muscle physiology, an action
potential causes membrane
depolarization which releases calcium
(Ca2+) from the sarcoplasmic reticulum
(SR). The Ca2+ is thus inserted into the
sarcoplasm via the ryanodine and
dihydropyridine receptors. Both of these
receptors are voltage-gated ion channels.
The Ca2+ then interacts with the
troponin-tropomyosin complex which
creates the cross-bridge between actin
and myosin and a muscle contraction
occurs. At the completion of the muscle
contraction, Ca2+ is sequestered back
into the sarcoplasmic reticulum and the
another stimulus is needed to release
Ca2+ for a muscle contraction
(Schneiderbanger et al., 2014).

Underlying
Pathophysiology
In MH, the mutated RYR1 gene
receptor threshold is decreased for Ca2+
release. The RYR1 receptors are also
resistant to the negative feedback loop
(increase Ca2+ and magnesium) that
would normally decrease the Ca2+
conductance.
This equates to an overt release of Ca2+,
in response to lower levels of membrane
depolarization. This causes an increased
amount of Ca2+ to be present in the
sarcoplasm which causes continuous and
prolonged muscle contractions when
attached to the troponin-tropomyosin
complex.
Adenosine triphosphate (ATP) is
consumed in every step of intracellular
Ca2+ interactions. These steps include:
- Decoupling of Ca2+ from troponin
- Removal of intracellular Ca2+
- Returning (Ca2+) to the SR and
mitochondria
- Extrusion into the extracellular milieu
(Hines & Marschall, 2012).
Oxygen and glycogen are thus used in
massive quantities by the mitochondria
as the body attempts to create more ATP
in response to the highly increased
metabolic demands. The metabolic
byproducts of this process are carbon
dioxide and lactate. In addition, the body
produces massive amounts of heat as the
ATP is used by muscles for contraction.

Rosenberg et al., (2015) stated that
some individuals have almost
immediate reactions with exposure to
triggers while others do not until well
into the post-operative period.
The early phase presents as a
masseter spasm, tachypnea (with
spontaneous ventilation), tachycardia
as well as an irregular heart heart, and
a rapid exhaustion of soda lime as well
as a warm soda lime container. The
anesthesia provider will begin to see an
increased minute ventilation, an
increased end-tidal CO2, and cardiac
dysrhythmias, as well as peaked T
waves. This is secondary to the patient
having an increased PaCO2, a metabolic
and respiratory acidosis, and
hyperkalemia due to the release of
potassium into the extracellular space
(Hines & Marschall, 2012).
The intermediate phase presents
with the continued irregular heart rate
but the patient would also be cyanotic
and warm to the touch. There will be
dark blood in the surgical site as
oxygen molecules would not be able to
bind to hemoglobin molecules as the
body is in an acidotic state as well as
the decreased transit time of blood
through the lungs, secondary to
tachycardia. The anesthesia provider
would thus observe an increasing core
body temperature and a decreasing
oxygen saturation. There would also be
persistent cardiac dysrhythmias and
peaked T waves secondary to
hyperkalemia (Hines & Marschall,
2012).
The late phase presents with a
generalized skeletal muscle rigidity
secondary to an increased intracellular
calcium and increased serum
creatinine kinase level. There will be a
prolonged bleeding time and cola
colored urine, secondary to
myoglobinuria associated with
rhabdomyolysis. As the patient
remains in a hyperkalemic state, the
anesthesia provider will continue to
notice cardiac dysrhythmias and
peaked T waves but will begin to
observe a widened QRS as well as
ventricular arrhythmias (Hines &
Marschall, 2012).

Significance Of Pathophysiology
Long & Ross (2017) stated that if MH is not treated, the body’s innate ability to
maintain homeostasis is overwhelmed and this can lead to cardiovascular collapse and
eventually death. Therefore, prompt recognition and intervention is necessary to prevent
irreversible damage. Hirchey Dirksen et al., (2013) stated that the MH response leads to a
variety of internal reactions secondary to the disruption of cell membranes such as an
increase in serum potassium, phosphate, magnesium, and myoglobin in the extracellular
fluid. Furthermore, the complications that can occur include permanent skeletal muscle
damage, hyperthermia (core temperatures between 39℃ & 41℃), renal failure
(secondary to rhabdomyolysis), cardiac arrest, and possible death.
Some of the short and long term complications of MH are rhabdomyolysis with an
accompanying compartment syndrome, disseminated intravascular coagulation (DIC),
heart failure, pulmonary edema, cerebral edema with or without herniation, acute liver
failure, shock secondary to a mixed metabolic and respiratory acidosis, bowel ischemia,
other end multi organ failure, cardiac collapse, and eventually death (Epocrates: An
Athenahealth Service, 2018).

Figure 1: Ryanodex, concentrated dantrolene sodium for use in a MH crisis (Ryanodex, 2018).

Implications for Nursing Care
Schneiderbanger et al., (2014) stated that the severity of a MH crisis depends on how
quickly the disease process is suspected and how rapidly an appropriate treatment is
initiated. Once MH has been recognized, it is imperative to discontinue the offending
triggering agent. Anesthesia should immediately be converted to total intravenous
anesthesia (TIVA) with the use of IV opioids, sedatives, and if the patient status
necessitates it, a non depolarizing muscle relaxant. The vaporizer that was used for
administration of the volatile anesthetic should be removed and the patient
hyperventilated with 100% oxygen at maximum fresh gas flow while an activated
charcoal filter is placed. There must also be an increase in the minute volume by 2x – 3x
times the patient’s baseline in an attempt to flush the volatile anesthetic from the patients
system while also aiming to decrease the end-tidal CO2 to within normal limits.
Hirchey Dirksen et al., (2013) states that the main medication that should be used in a
MH crisis is dantrolene sodium at 2.5 mg/kg IV every 5-10 minutes based on actual body
weight. Long & Ross (2017) state that this medication interferes with the release of Ca2+
from the SR which results in a decrease in the Ca2+ in the myoplasm. This is because
dantrolene is a specific ryanodine receptor antagonist. It is recommended that 36 vials of
dantrolene be stocked at any facility where the causative agents of MH are used to treat a
patient in MH crisis as they will require a very large quantity of dantrolene.
Once a MH crisis has been confirmed, and the administration of dantrolene has begun,
other supportive measures must be started. Hirchey Dirksen et al., (2013) states to
administer sodium bicarbonate to correct the acid-base balance secondary to the mixed
respiratory and metabolic acidosis.

Implications Continued
The patient must also be cooled via
administration of cold IV fluids, being
packed with ice packs, having cold
irrigation fluids instilled into open body
cavities as well as having a cold lavage
of the stomach, rectum, and bladder as
well as the application of hypothermia
blanket.
Diuretics, such as furosemide, must
also be administered to reduce the
incidence of fluid overload as well as the
promotion of the excretion of
potassium, sodium, and myoglobin.
Dantrolene, per 20 mg vial, also
contains 3 g of mannitol, an osmotic
diuretic which will help in this process.
To correct the marked hyperkalemia,
glucose and insulin, as well as sodium
bicarbonate, calcium chloride, or
calcium gluconate can be administered.
The patient can also benefit from an
antiarrhythmic to treat dysrhythmias
that have not responded to the
treatment of acidosis and hyperkalemia.
The implementation of standard
advanced cardiac life support (ACLS)
measures is paramount with the
exception of calcium channel blockers
which can cause hyperkalemia and/or
cardiac arrest in the presence of
dantrolene.

Differential
Diagnosis
Malignant hyperthermia requires a
high degree of suspicion when early
signs and symptoms are present.
Unfortunately, the early signs and
symptoms of MH are nonspecific and
present as other hypermetabolic states
would. The hypermetabolic states in
question are:
Non-MH Rhabdomyolysis
Muscle disuse atrophy
Myotonia
Sepsis
Complications of laparoscopic surgery
Allergic reactions
Serotonin syndrome
Hyperthyroidism
Neuroleptic malignant syndrome
Baclofen with-drawl syndrome

Differential
Diagnosis
Continued
Thyrotoxocosis
Pheochromocytoma
Metastatic carcinoid
Drug induced muscle injury
MDMA overdose
Use of designed drugs of new
psychoactive substances
Alpha PVP or “Flakka”
Exertional heat stroke
Thermal dysregulation
Iatrogenic overheating
Meperidine/MAOI overdose
Cocaine intoxification
(Epocrates: An Athenahealth Service,
2018).
According to Rosenberg et al., (2015),
patients with Central Core Disease,
(CCD), Multi-minicore Disease (MmD),
central nuclear myopathy, and KingDenborough syndrome are predisposed
to episodes of MH.

Clinical Resources
In the clinical setting, the anesthesia
provider and support staff must be able
to quickly address and treat MH. One of
the primary resources that the
healthcare provider has available is the
Malignant Hyperthermia Association of
the United States (MHAUS). This
association can help facilities prepare
for an MH emergency as well as manage
a crisis in real time. They can be reached
at:
1-800-644-9737
24 hours a day/7 days a week and
providers are encouraged to call if MH
is suspected (Malignant Hyperthermia
Association of the United States, 2018).
Cain et al., (2014) stated that MH, a
rare yet life-threatening event, can put
clinicians at a disadvantage if they are
unprepared to manage an MH crisis.
The author of this article went on to
indicate that a facilitated simulation of
how to respond and treat MH in a safe
environment can help clinical staff
identify where improvement in gaps of
knowledge and skills are needed. Two
major points that came from the
training exercise was the importance of
role assignments, as well as the use of
visual aids, when training for an MH
crisis.

Conclusions
Banek et al., (2013) stated that MH is
a rare but potentially lethal genetic
disease process that presents as
muscle hypermetabolism upon
exposure to certain anesthetic agents.
Rosenberg et al., (2015) stated that
the main clinical features of MH are:
1) Unexplained elevation of expired
carbon dioxide despite an
increased minute ventilation
2) Muscle rigidity with an associated
Rhabdomyolysis
3) Hyperthermia
4) Tachycardia
5) Acidosis [metabolic and
respiratory]
6) Hyperkalemia
According to Hirchey Dirksen et al.,
(2013), the use of dantrolene sodium,
in combination with early recognition,
accurate diagnosis, and appropriate
treatment, has decreased rates of
mortality from 80% in the 1970s to
approximately 5% as of 2007.
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